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The costs of heart operations and the problems related to anticoagulation after 
prosthetic valve replacement are among the limitations faced by patients in 
nonindustrialized countries with mitral stenosis caused by chronic rheumatic 
heart disease. The young age at which these patients are seen also compels the 
surgeon to preserve the native valve. The least costly and optimal way to 
achieve this objective is by closed mitral valvotomy. After closed mitral 
valvotomy, mitral restenosis is commonly encountered. We report here our 
10-year experience with operation on 113 consecutive patients with mitral 
restenosis. Closed transventricular evalvotomy was performed with Tubbs 
dilator in 105 of 113 patients. Mean age was 34.3 years, with a male to female 
ratio of 1:1.5. Most patients were in New York Heart Association functional 
classes III and IV (74.3% and 19.4%, respectively). Mean interval between first 
and second valvotomy was 9.4 years. Hospital mortality rate was 2.8%, trivial 
postoperative mitral regurgitation occurred in 16.1%, and moderately severe 
regurgitation occurred in 1.9%. Early postoperative systemic embolism oc- 
curred in 3.8% of the cases. Moderate to excellent symptomatic improvement 
was noted in 89.4% of the cases and poor results were seen in 10.2%. Late 
follow-up of 76 patients ranged from 2 to 10 years (mean 3.8 years), with 
39.4% patients in New York Heart Association class I and 50% in class II. 
Close mitral revalvotomy is thus an economical, simple, and safe palliative 
procedure that carries good long-term results. (J Thorac Cardiovasc Surg 
1996;112:727-30) 
W ith the introduction of cardiopulmonary by- pass, the technique of closed transventricular 
mitral valvotomy (CMV) for mitral stenosis was 
virtually abandoned in industrialized countries. This 
technique continues to be used in most centers in 
nonindustrialized countries, however, because of its 
cost-effectiveness and to avoid the problem of anti- 
coagulation therapy after prosthetic mitral valve 
replacement (MVR). Restenosis i a known compli- 
cation after CMV, and its prevalence has been 
reported to range widely, varying between 2% and 
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60%. 1-3 Approximately 10% of patients returning to 
the hospital with persistent or recurrent symptoms 6 
years after operation have true restenosis, 4 Virtually 
no differences have b en reported with respect o 
the short-term results achieved with the three 
available palliative procedures: CMV, open mitral 
valvotomy or commissurotomy (OMV), and balloon 
mitral valvotomy (BMV). s It will take more time, 
however, for evaluation of long-term results of 
OMV and BMV. 
Considering the relatively ounger age at which our 
patients are seen and their socioeconomic status, our 
effort has been to adopt a palliative procedure with a 
low cost and without problems of anticoagulation, 
while at the same time preserving the native valve. In 
this retrospective study, we analyzed the results of 
CMV in 105 of total 113 consecutive patients with 
mitral restenosis at the Post Graduate Institute of 
Medical Education and Research, Chandigarh, India. 
Patients and methods 
This study comprises 113 consecutive patients with 
mitral restenosis who underwent reoperation during a 
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Table I. Patient age at CMR (n = 113) 
Age group 
(yr) No. % 
13-25 13 11.5 
26-40 71 62.8 
41-50 24 21.2 
>50 05 4.4 
TOTAL 113 - -  
Table II. Preoperative chocardiographic f ndings 
(n = 113) 
Pathology No. % 
Calcification 43 38.0 
Mild 24 21.2 
Moderate 13 11.5 
Severe 6 5.3 
Subvalvular pathology 78 68.9 
Mild 46 40.7 
Moderate 28 24.7 
Severe 4 3.5 
Left atrial clot 2 1.7 
Mean valve area 0.74 cm 2. 
10-year period (January 1982 to December 1992). These 
patients were evaluated clinically and echocardiographi- 
cally. Most were found to be suitable candidates for closed 
mitral revalvotomy (CMR). Six patients with heavily cal- 
cified valves underwent MVR, and two patients in whom 
a left atrial clot was detected on echocardiography under- 
went OMV. In the remaining 105 patients, CMR was 
carried out. One hundred two of these patients underwent 
CMR for the first time and three patients had successful 
second CMRs. Patients who had symptoms within 3 years 
of the first CMV were excluded from this study because 
they were considered to have an inadequate initial valvo- 
tomy. 
Of 113 patients with mitral restenosis, 45 were male and 
68 were female (1:1.5). Their ages ranged from 14 to 56 
years, with a mean of 34.3 years (Table I). Most of the 
patients were in New York Heart Association functional 
classes lII (74.3%) and IV (19.4%). Hemoptysis was 
present in 15.9% of the patients, and atrial fibrillation was 
present in 55% of the patients. Preoperative systemic 
embolic episodes occurred in 11 patients (10%), with 
detectable ft atrial clot in only two. The mean interval 
between first CMV and CMR was 9.4 years; that between 
first CMV and MVR was 6.2 years. Preoperative echocar- 
diographic findings are listed in Table II. Mean mitral 
valve area according to echocardiography was 0.74 cm 2. 
A left anterolateral thoracotomy approach was used for 
all patients. Through the previous incision scar, the chest 
was entered through the bed of the fifth rib. Adhesions 
were separated by sharp dissection to expose the body of 
the left atrium, adjacent left superior pulmonary vein, and 
left ventricular apex. Double purse-string sutures of 2-0 
Prolene (Ethicon, Inc., Somerville, N.J.) or silk were 
placed over the body of left atrium, extending onto the 
Table III. Operative complication of CMR (105 
cases) 
Complication No. % 
Mitral regurgitation 19 18.0 
TrMal 17 16.1 
Severe 2 1.9 
Systemic embolism 4 3.8 
Intraoperative hypotension 12 11.4 
Intraoperative ventricular 3 2.8 
fibrillation 
Failure to dilate valve 1 0.9 
entry of left superior pulmonary vein, for introduction of 
the surgeon's right index finger. Another mattress suture 
with 2-0 silk was placed at the left ventricular apex 
adjacent to the previous ventriculotomy site for introduc- 
tion of a Tubbs dilator. The orifice of the mitral valve was 
dilated to 3.25 or 3.5 cm in diameter. 
A total of 76 patients who had undergone CMR were 
evaluated clinically and with echocardiography. Evalua- 
tion was performed 2 to 10 years (mean 3.8 years) after 
operation. 
Results 
A complete and satisfactory commissurotomy was 
achieved in 95 of the 105 patients who underwent 
CMR. In one case, the procedure had to be aban- 
doned because the Tubbs dilator could not be 
negotiated across the mitral valve orifice as a result 
of severe subvalvular pathology. Postcommissur- 
otomy mitral regurgitation occurred in 19 patients. 
Regurgitation was trivial in 17 patients (16.1%) and 
moderately severe in two patients (1.9%). Of the 
two patients with moderately severe mitral regurgi- 
tation, one underwent emergency MVR and the 
other died before operation of acute intractable 
pulmonary edema and low cardiac output. Postop- 
erative systemic embolism occurred in four patients 
(3.8%). Intraoperative ventricular fibrillation that 
could be successfully converted with direct current 
shock occurred in three patients. Operative compli- 
cations are listed in Table III. Early in-hospital 
death (defined as death occurring within 30 days 
after operation) after CMR was 2.8%. There were 
no operative complications in the three patients who 
underwent a second CMR. Causes of death after 
CMR for mitral restenosis are shown in Table IV. 
Ecfiocardiography from 84 patients at first fol- 
low-up (1 to 3 months) showed adequate valvotomy 
(mitral valve area ->1.75 cruZ) in 88.1% and inade- 
quate valvotomy (mitral valve area <1.75 cruZ) in 
11.9%. Mean mitral valve area was 1.82 cruZ. The 
functional statuses of 76 patients at 2- to 10-year 
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Table IV. Cause of  death after CMR (n = 105) 
Cause No. 
Cerebral embolism 1 
Low cardiac output with mitral 1 
regurgitation 
Ventricular arrhythmia 1 
Total deaths 3 
follow-up (mean 3.8 years) are shown in Table V. 
The occurrences of restenosis were 8.4 at 5 years 
and 20.2 at 10 years per 1000 patients per year after 
CMR. None of our patients had any evidence of 
recurrence of acute rheumatic activity. There was no 
subsequent increase in mitral regurgitation among 
patients in whom trivial mitral regurgitation periop- 
erative had developed. 
Discussion 
CMV is an established surgical procedure for 
treatment of mitral restenosis, however, only a few 
studies assessing its results have been reported. 1'6, 7 
The current consensus in industrialized countries 
favors open operative techniques. 2' 8 Despite many 
reports on the effectiveness of OMV, it is not certain 
whether the results are sufficiently superior to those 
of CMV to justify the higher cost involved in an 
open procedure, an important factor particularly in 
nonindustrialized countries. 9 Farhat and associ- 
ates 1° reported a mean mitral valve area of 2.1 cm 2 
after OMV for noncalcific mitral stenosis. In earlier 
reports, survival after CMV was rather disappoint- 
ing.~l, 12 Recent studies, however, have shown low 
early and late mortality rates after CMV both for 
primary mitral stenosis and restenosis. 1' 6, 13 MVR 
carries the risk of thromboembolism, echanical 
failure, prosthetic valve endocarditis, and problems 
related to anticoagulation. The incidences of mitral 
regurgitation after CMV and OMV are similar. The 
reported incidence of MVR after OMV in a fol- 
low-up of 4.4 years to 8.6 years is 7% to 18%. 2, 14 
Younger surgeons have shown a preference for 
MVR.lS, 16 
Although BMV has recently gained populari- 
ty, lO, 17-20 its cost and short-term palliative results 
compared with those achieved by CMV are limiting 
factors. 21 In the available literature, there are no 
reports defining the role of percutaneous BMV for 
mitral restenosis. 22The results of surgical commis- 
surotomy (OMV, CMV) and BMV are simi- 
lar,~4, 23, 24 and only the patient's preference and the 
cost factor guide the choice of the procedure to be 
Table V. Functional status at late follow-up (2 to 
lO yr, mean 3.8 yr; n = 76) 
Preoperative Postoperative 
NYHA Functional 
Class No. % No. % 
I 0 0 30 39.4 
II 4 5.2 38 50 
III 62 81.5 6 7.6 
IV 10 13.1 2 2.6 
NYHA, New York Heart Association. 
performed. In an editorial, Frater 5 cautioned that 
the results achieved by BMV are as good as those of 
CMV, provided that complications (including resid- 
ual atrial septal defect, cardiac perforation, and 
iatrogenic mitral regurgitation) are not in excess of 
those associated with operation. It has been pre- 
dicted that in appropriately selected patients the 
long-term clinical outcome after BMV may be ex- 
pected to be similar to the available data for surgical 
commissurotomy (OMV, CMV)Y 
Restenosis is the result not only of inadequate 
valvotomy but also of a continuing fibrotic process. 1 
Progressive restenosis correlates not only with time 
but also with the pathologic state of valve at surgical 
intervention. 5 The relatively younger age of our 
patients, a mean of 34.3 years, forced us to evolve a 
strategy to conserve the native valve through CMV 
or CMR. Any other procedure would have led to 
increased costs and lesser acceptability of a valvular 
prosthesis in our social milieu. Logically, the basic 
social circumstances and inadequate health care 
facilities available for our population group at risk, 
compels us to adopt the most cost-effective proce- 
dures in our country. The results have been so 
gratifying in our patients that we believe every effort 
should be made to preserve the native valve until a 
more acceptable valve substitute is available. 
MVR caries the hazards of anticoagulation, with 
the necessity of life-long expenditure and strict 
treatment compliance. Because most of our popu- 
lation at risk has a rural background and poor 
socioeconomic status, compliance with an anticoag- 
ulation schedule is always doubtful in our country, 
and noncompliance often leads to serious post- 
MVR complications. 
In our experience, the early operative mortality 
rate is less than that reported for earlier series, 6' 13 is 
easily comparable with that of OMV, 8' 26, 27 and is 
certainly less than that for MVR. 28 Mitral regurgi- 
tation carries an important prognostic significance 
for functional outcome necessitating MVR 19' 2o but 
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was trivial in most of our cases (16.1%). There is no 
reported difference in the prevalences of mitral 
regurgitation associated with the three palliative 
procedures available for the treatment of mitral 
stenosis. 25 The l imitation common to CMV, BMV, 
and OMV is calcified valve; that common to both 
CMV and BMV is left atrial clot. 
Conclusion 
New York Heart  Association functional class 
improved in most of our patients after CMR. In our 
opinion, CMV for mitral restenosis still offers excel- 
lent pall iation with low r isk,  low cost, and good 
long-term results in most patients, without the haz- 
ards of anticoagulation. 
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